Dechra Pharmaceuticals PLC Director/PDMR Shareholding (3998B)

TIDMDPH

RNS Number : 3998B

Dechra Pharmaceuticals PLC

07 October 2020

7 October 2020

Dechra Pharmaceuticals PLC

(the Company)

Notification of Transactions by Persons Discharging Managerial Responsibilities

Dechra Pharmaceuticals PLC has been notified that on 6 October 2020 Lisa Bright, Non-Executive Director, purchased 788 ordinary shares in the Company.

Following this acquisition, Lisa Bright's beneficial interest in the Company is 788 shares (0.001% of the current issued share capital).

The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                                  Lisa Bright 
     ------------------------------------  ---------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                       Director 
     ------------------------------------  ---------------------------------- 
 b)   Initial notification/                 Initial Notification 
       amendment 
     ------------------------------------  ---------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                                  Dechra Pharmaceuticals PLC 
     ------------------------------------  ---------------------------------- 
 b)   LEI code                              213800J4UVB5OWG8VX82 
     ------------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of                        Ordinary Shares of 1 pence each 
       the financial 
       instrument 
                                             ISIN: GB0009633180 
       Identification 
       code 
     ------------------------------------  ---------------------------------- 
 b)   Nature of the                         Purchase of Shares 
       transaction 
     ------------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)                Price(s)          Volume(s) 
                                             GBP32.52          788 
     ------------------------------------  ----------------  ---------------- 
 d)        Aggregated information 
             *    Aggregate volume            788 
                                              GBP32.52 
                                              GBP25,625.76 
             *    Price 
 
 
             *    Total 
     ------------------------------------  ---------------------------------- 
 e)   Date of the transaction               2020-10-06 
     ------------------------------------  ---------------------------------- 
 f)   Place of the transaction              London Stock Exchange 
     ------------------------------------  ---------------------------------- 
 

For further information, please contact:

Melanie Hall, Company Secretary

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKKOBKDBDDOKK

(END) Dow Jones Newswires

October 07, 2020 07:09 ET (11:09 GMT)